• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » First Non-Drug Treatment Approved by FDA for Treating Children With ADHD

First Non-Drug Treatment Approved by FDA for Treating Children With ADHD

June 11, 2019
Talia Puzantian, PharmD, BCPP and Joshua Feder, MD
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

NeuroSigma made a splash by announcing that the FDA has granted medical device approval for its external Monarch Trigeminal Nerve Stimulation (eTNS) System for treating kids with ADHD ages 7–12 who are not currently taking medications.

What does medical device approval mean?
The FDA reviewed the Monarch eTNS System through the de novo ­pre-market review pathway, a less rigorous process than the usual pre-marketing approval process. This is a regulatory pathway for low- to moderate-risk devices of a new type, which asserts that the device is safe to use. The process does not affirm effectiveness of the device for the intended use. This level of approval means that subsequent devices of the same type with the same intended use may go through a process that allows the manufacturer to market its device just by demonstrating equivalence to this first (de novo) device.

How does it work?
The cellphone-sized device is meant to be used at home, under a caregiver’s supervision, for 8 hours while the child sleeps. The device has a thin wire that connects to a small adhesive electrode patch, which is placed on the child’s forehead just above the eyebrows. It provides a low-level electrical pulse (120 Hz frequency and cycles of 30 seconds on/off with 2–4 milli-amperes of current), causing mild stimulation to branches of the trigeminal nerve.

Is it effective?
A small 4-week study of kids with moderate to severe ADHD compared treatment with eTNS (n = 32) to a sham placebo device (n = 30). The primary outcome measured was the clinician-administered ADHD Rating Scale ­(ADHD-RS) total score. Although only slightly more than half of eTNS kids had clinically meaningful improvement, a statistically significant reduction was seen compared to placebo (eTNS score 34.1 at baseline to 23.4 at 4 weeks vs placebo device score 33.7 at baseline to 27.5 at 4 weeks), though improvement was seen in both groups. The estimated effect size of 0.5 is similar to the effect sizes seen with non-stimulant medications used to treat ADHD (a medium effect). The number-needed-to-treat (NNT) based on Clinical Global Impression—Improvement (CGI-I) scores at week 4 was 3. This means 3 people would need to be treated to find one who responds (in other words, for every patient who does better than placebo, 2 would have done just as well on ­placebo).

Is it safe?
Most kids will feel a tingling sensation on the skin. Drowsiness, increased appetite, trouble sleeping, teeth clenching, headache, and fatigue were the side effects most commonly reported in the study. A statistically significant increase in heart rate was seen, but pulse rates were still in the normal range and kids were not symptomatic. Weight gain was also statistically significantly greater in the eTNS group. Skin whitening or discoloration under the patch was seen in both groups, particularly in darker-skinned kids. This was attributed to loss of superficial skin layers when the patch was removed, and the discoloration resolved over time and with sun exposure.

How much will it cost?
The prescription-only device will be available from NeuroSigma “in the coming months,” and pricing information is not yet available, although some accounts have priced starter kits at $900.

CCPR’s Take
This is an interesting “gee whiz” device that will no doubt capture the imagination of families looking for a simple approach who don’t want their kids treated with medications, cognitive behavioral therapy (CBT), or parent training, even though these have a proven track record of safety and efficacy. We’re going to need more data than 62 kids in a 4-week manufacturer-run study to understand eTNS’ place in therapy for kids with ADHD. Moreover, the weight gain seen in this study begs for more investigation, perhaps having to do with changes in sleep and cortisol.
Child Psychiatry
KEYWORDS adhd adolescents attention-deficit-hyperactivity-disorder brain_devices child_psychiatry children efficacy etns news_of_note pediatric safety teens treatment trigeminal-nerve-stimulation
    Puzantian 150x150
    Talia Puzantian, PharmD, BCPP

    Medication Fact Book for Psychiatric Practice, Seventh Edition (2024)

    More from this author
    Eic photo joshua d feder md jpg 150x150
    Joshua Feder, MD

    SSRIs and Hydroxyzine for Avoidant/Restrictive Food Intake Disorder (ARFID)?

    More from this author
    www.thecarlatreport.com
    Issue Date: June 11, 2019
    SUBSCRIBE NOW
    Table Of Contents
    Note From the Editor-in-Chief
    Medications for Depression
    Practical Approaches to Vetting Clinical Research
    FDA Approves Adhansia XR
    First Non-Drug Treatment Approved by FDA for Treating Children With ADHD
    Prescribing Patterns for Children With Anxiety Disorders
    Melatonin for Insomnia in Patients With Autism
    Steroid-Induced Psychosis in the ­Pediatric Population
    Risk of Psychosis With Stimulants in ADHD Patients
    Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents
    CME Post-Test - Depression in Children and Adolescents, CCPR, Summer 2019
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.